Skip to main content
GutCited
Figure 6

描述

Comparative analysis of individual IBS symptom domains across treatment groups, evaluating the differential effects of the inulin-choline-silymarin supplement.

More Figures from This Paper

Symptom severity distribution at the initial evaluation, revealing that approximately half of the IBS-C patients presented with moderate symptoms while over 40% had severe manifestations.

Figure 7

Symptom severity distribution at the initial evaluation, revealing that approximately half of the IBS-C patients presented with moderate symptoms while over 40% had severe manifestations.

chart
Total IBS symptom scores measured at the 28-day assessment point, comparing outcomes between the supplemented and control diet groups in the crossover design.

Figure 8

Total IBS symptom scores measured at the 28-day assessment point, comparing outcomes between the supplemented and control diet groups in the crossover design.

chart
Analysis of gastrointestinal symptom domains in the IBS-C study at an intermediate time point, tracking changes in bloating, pain, and bowel habit parameters.

Figure 9

Analysis of gastrointestinal symptom domains in the IBS-C study at an intermediate time point, tracking changes in bloating, pain, and bowel habit parameters.

chart
Stool frequency and consistency measurements during the treatment phase, evaluating whether inulin-based supplementation improved bowel regularity in IBS-C patients.

Figure 10

Stool frequency and consistency measurements during the treatment phase, evaluating whether inulin-based supplementation improved bowel regularity in IBS-C patients.

chart
Quality of life assessment data from IBS-C patients, comparing self-reported well-being between supplementation and control periods.

Figure 11

Quality of life assessment data from IBS-C patients, comparing self-reported well-being between supplementation and control periods.

chart
Individual patient response trajectories over the treatment period, illustrating the variability in symptom improvement with the prebiotic supplement.

Figure 12

Individual patient response trajectories over the treatment period, illustrating the variability in symptom improvement with the prebiotic supplement.

chart

Figure 6

Chart
773 × 570px · 24.2 KB

Source Paper

Inulin, Choline and Silymarin in the Treatment of Irritable Bowel Syndrome with Constipation-Randomized Case-Control Study.

Journal of clinical medicine (2022)

PMID: 35456341

DOI: 10.3390/jcm11082248

Cite This Figure

![Figure 6: Comparative analysis of individual IBS symptom domains across treatment groups, evaluating the differential effects of the inulin-choline-silymarin supplement.](https://pdfs.citedhealth.com/figures/35456341/70.png)

> Source: Oana-Bogdana Bărboi et al. "Inulin, Choline and Silymarin in the Treatment of Irritable Bowel Syndrome with ." *Journal of clinical medicine*, 2022. PMID: [35456341](https://pubmed.ncbi.nlm.nih.gov/35456341/)
<figure>
  <img src="https://pdfs.citedhealth.com/figures/35456341/70.png" alt="Comparative analysis of individual IBS symptom domains across treatment groups, evaluating the differential effects of the inulin-choline-silymarin supplement." />
  <figcaption>Figure 6. Comparative analysis of individual IBS symptom domains across treatment groups, evaluating the differential effects of the inulin-choline-silymarin supplement.<br>  Source: Oana-Bogdana Bărboi et al. "Inulin, Choline and Silymarin in the Treatment of Irritable Bowel Syndrome with ." <em>Journal of clinical medicine</em>, 2022. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/35456341/">35456341</a></figcaption>
</figure>

相关证据

B
Inulin 用于 Chronic Constipation

等级 B · 6 项研究